Robert W. Baird set a $20.00 price target on Amicus Therapeutics (NASDAQ:FOLD) in a research report sent to investors on Wednesday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other brokerages have also recently commented on FOLD. ValuEngine upgraded Amicus Therapeutics from a sell rating to a hold rating in a report on Friday, February 2nd. BidaskClub upgraded Amicus Therapeutics from a hold rating to a buy rating in a report on Monday, January 15th. Zacks Investment Research upgraded Amicus Therapeutics from a hold rating to a buy rating and set a $16.00 target price for the company in a report on Tuesday, October 10th. Finally, Cowen restated a buy rating and set a $22.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 10th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $18.56.

Shares of Amicus Therapeutics (FOLD) traded down $0.28 during trading on Wednesday, reaching $16.60. The company had a trading volume of 1,106,358 shares, compared to its average volume of 3,069,411. Amicus Therapeutics has a 12 month low of $5.87 and a 12 month high of $17.40. The stock has a market cap of $2,810.00, a PE ratio of -9.06 and a beta of 1.45. The company has a quick ratio of 6.22, a current ratio of 6.32 and a debt-to-equity ratio of 0.39.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The firm had revenue of $10.90 million for the quarter, compared to analysts’ expectations of $9.02 million. During the same quarter last year, the business earned ($0.33) earnings per share. The business’s revenue was up 419.0% compared to the same quarter last year. equities research analysts anticipate that Amicus Therapeutics will post -1.52 EPS for the current year.

In other news, COO Bradley L. Campbell sold 32,500 shares of Amicus Therapeutics stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $15.92, for a total value of $517,400.00. Following the completion of the transaction, the chief operating officer now owns 186,600 shares in the company, valued at approximately $2,970,672. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John F. Crowley sold 47,213 shares of Amicus Therapeutics stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $13.61, for a total value of $642,568.93. Following the completion of the transaction, the chief executive officer now owns 375,214 shares of the company’s stock, valued at approximately $5,106,662.54. The disclosure for this sale can be found here. Insiders sold a total of 250,390 shares of company stock valued at $3,620,581 in the last quarter. Company insiders own 3.40% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in FOLD. Janus Henderson Group PLC purchased a new position in shares of Amicus Therapeutics in the 2nd quarter valued at about $70,762,000. Eagle Asset Management Inc. purchased a new position in shares of Amicus Therapeutics in the 3rd quarter valued at about $40,450,000. Jennison Associates LLC lifted its stake in Amicus Therapeutics by 9.4% during the third quarter. Jennison Associates LLC now owns 9,772,025 shares of the biopharmaceutical company’s stock worth $147,362,000 after purchasing an additional 838,267 shares during the last quarter. Allianz Asset Management GmbH purchased a new stake in Amicus Therapeutics during the third quarter worth approximately $11,381,000. Finally, Perceptive Advisors LLC lifted its stake in Amicus Therapeutics by 3.4% during the third quarter. Perceptive Advisors LLC now owns 17,888,597 shares of the biopharmaceutical company’s stock worth $269,760,000 after purchasing an additional 591,925 shares during the last quarter.

WARNING: This article was first reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2018/02/08/amicus-therapeutics-fold-given-a-20-00-price-target-by-robert-w-baird-analysts.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.